Nottingham biosciences million pound injection

The investment, under the Translation Award programme, will help Nottingham-based RegenTec Ltd to develop commercial products in the rapidly-developing field of regenerative medicine. The company has perfected techniques which could greatly enhance the repair of bone defects and fractures.

RegenTec Ltd was created to build on the world-changing research carried out by scientists at The University of Nottingham, Britain’s ‘University of the Year’. With support from the East Midlands Development Agency, the company has invented a unique material that works with stem cells and biopharmaceuticals to stimulate the regeneration of tissue in patients.

When injected into the body the material forms a highly porous scaffold structure, which encourages new tissues to form.

The unique scaffold mechanism also assists the delivery of stem cells and drugs without compromising their effectiveness. This offers a substantial opportunity to deliver a cure to patients with bone, liver, heart or nerve tissue defects.

Professor Kevin Shakesheff, Chief Scientific Officer at RegenTec, and Director of The Centre for Biomolecular Sciences at The University of Nottingham, said: “The ability to inject these scaffold materials could significantly reduce the need for invasive surgery in tissue repair.

“It will mean that operation and rehabilitation times could come down significantly. After injection, the porous material we use gradually degrades, leaving behind only newly formed bone tissue.”

RegenTec has developed an extensive portfolio of patents and hopes that its injectable technology can reach clinics within three years. Its first product – Injectabone – will be used as a replacement for bone grafting, which can be beset by problems which include a short supply of host bone, chronic post-operative pain, and an increased risk of infection. Injectabone will be launched in the US and European markets for use by orthopaedic surgeons.

The material will then be adapted to help in treatment of many other diseases.

Dr Robin Quirk, Managing Director, said: “Regenerative medicine is a hugely exciting worldwide industry that promises to radically improve many aspects of clinical practice. We have a world-first technology that has a remarkable range of future uses.

“The Wellcome Trust Award is a substantial step forward in ensuring that the UK plays a major role in the commercial and clinical development of regenerative medicine.”

Dr Susan Huxtable, Director of Intellectual Property and Commercialisation at The University of Nottingham, said: “The Wellcome Trust Award is recognition of the hard work and creativity of a large team of scientists who have worked at the University of Nottingham and within Regentec over the past five years.

“They are pioneers in terms of their science, but also in ensuring that the expertise and knowledge honed in a research-intensive university can be translated into commercial enterprise, and make a dynamic contribution to well-being and economic growth. We have enjoyed a record year in attracting third party investment to our portfolio of spin-out companies.”